Black Diamond Therapeutics Inc (NASDAQ: BDTX) kicked off on Tuesday, down -2.05% from the previous trading day, before settling in for the closing price of $2.92. Over the past 52 weeks, BDTX has traded in a range of $1.62-$7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 23.44%. With a float of $43.06 million, this company’s outstanding shares have now reached $51.65 million.
In an organization with 54 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.91%, operating margin of -1782.65%, and the pretax margin is -1645.87%.
Black Diamond Therapeutics Inc (BDTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Black Diamond Therapeutics Inc is 23.80%, while institutional ownership is 72.15%. The most recent insider transaction that took place on Aug 28 ’24, was worth 1,400,556. In this transaction 10% Owner of this company sold 221,600 shares at a rate of $6.32, taking the stock ownership to the 3,726,341 shares. Before that another transaction happened on Jul 31 ’24, when Company’s Former Employer proposed sale 50,000 for $6.20, making the entire transaction worth $310,000.
Black Diamond Therapeutics Inc (BDTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 23.44% per share during the next fiscal year.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Take a look at Black Diamond Therapeutics Inc’s (BDTX) current performance indicators. Last quarter, stock had a quick ratio of 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.54, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.81 million. That was inferior than the volume of 0.83 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.16%. Additionally, its Average True Range was 0.27.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 1.77%, which indicates a significant decrease from 8.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.68% in the past 14 days, which was lower than the 86.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.61, while its 200-day Moving Average is $4.89. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $2.93. Second resistance stands at $2.99. The third major resistance level sits at $3.06. If the price goes on to break the first support level at $2.79, it is likely to go to the next support level at $2.72. Assuming the price breaks the second support level, the third support level stands at $2.66.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
The company with the Market Capitalisation of 161.59 million has total of 56,505K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -82,440 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -19,910 K.
